专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL238036D0 A solid oral pharmaceutical formulation containing ticagrelor 未知
公开(公告)号：IL238036D0
公开(公告)日：2015-05-31
申请号：IL23803615
申请日：2015-03-30
申请人： ZENTIVA KS , SEDMAK GREGOR
发明人： SEDMAK GREGOR
IPC分类号： A61K20060101
摘要： The present solution provides a solid oral pharmaceutical formulation containing ticagrelor, in the chemical name (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]- 5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2- cyclopentanediol, comprising at least one non-hygroscopic filler and/or at least one non- hygroscopic binder, wherein neither the filler, nor the binder have any disintegration effect. Preparation of the formulation is possible by wet granulation or dry granulation or direct

2. 发明申请

WO2010146187A3 PROCESS FOR THE PREPARATION OF TELMISARTAN 审中-公开
标题翻译：制备泰米斯坦的方法
公开(公告)号：WO2010146187A3
公开(公告)日：2011-02-24
申请号：PCT/EP2010058754
申请日：2010-06-21
申请人： KRKA TOVARNA ZDRAVIL D D NOVO MESTO , ZUPANCIC SILVO , SEDMAK GREGOR
发明人： ZUPANCIC SILVO , SEDMAK GREGOR
IPC分类号： C07D235/20 , A61K31/4184 , A61P9/12
CPC分类号： C07D235/20
摘要： The invention relates to processes for preparing telmisartan or a pharmaceutically acceptable salt thereof as well as to a process for preparing a telmisartan cyano intermediate. Moreover, the invention relates to a multilayer pharmaceutical tablet comprising (a) at least one first tablet layer comprising 1 to 50 wt. -% telmisartan or a pharmaceutically acceptable salt thereof by weight of the first tablet layer and (b) at least one second tablet layer comprising 1 to 50 wt.-% of a diuretic and 50 to 99 wt.-% of at least one filler by weight of the second tablet layer, wherein the combined weight of the diuretic and the at least one filler is at least 87 wt.-% by weight of the second tablet layer. The invention also relates to a process for the preparation of a multilayer pharmaceutical tablet.
摘要翻译：本发明涉及制备替米沙坦或其药学上可接受的盐以及制备替米沙坦氰基中间体的方法。此外，本发明涉及一种多层药物片剂，其包含（a）至少一种第一片剂层，其包含1至50重量％ - 替米沙坦或其药学上可接受的盐，和（b）至少一个第二片剂层，其包含1至50重量％的利尿剂和50至99重量％的至少一种填料的第二片剂层，其中利尿剂和至少一种填料的组合重量为第二片剂层重量的至少87重量％。本发明还涉及制备多层药物片剂的方法。

3. 发明申请

WO2009013237A3 STABLE SOLID PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN OR PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF 审中-公开
标题翻译：稳定的固体药物组合物，包含糖果或其药物可接受的形式
公开(公告)号：WO2009013237A3
公开(公告)日：2009-10-29
申请号：PCT/EP2008059451
申请日：2008-07-18
申请人： KRKA D D NOVO MESTO , SEDMAK GREGOR , TURK URSKA , SMRKOLJ MATEJ , ZUPANCIC SILVO
发明人： SEDMAK GREGOR , TURK URSKA , SMRKOLJ MATEJ , ZUPANCIC SILVO
IPC分类号： A61K9/20 , A61K9/48 , A61K31/4184
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/205 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K31/4184
摘要： The invention relates to a stable solid pharmaceutical composition comprising candesartan or its pharmaceutically acceptable forms and at least one plasticizer selected from the group consisting of phthalate esters, sebacates, alginates, citrate esters, polyacrylate and polymethacrylate polymers, polymers and copolymers of ethylene, vinyl and/or acetate, various sugar alcohols, triacetin, menthol and any mixture thereof.
摘要翻译：本发明涉及稳定的固体药物组合物，其包含坎地沙坦或其药学上可接受的形式和至少一种选自邻苯二甲酸酯，癸二酸酯，藻酸盐，柠檬酸酯，聚丙烯酸酯和聚甲基丙烯酸酯聚合物的增塑剂，乙烯，乙烯基和乙烯基的聚合物和共聚物 /或乙酸盐，各种糖醇，甘油三乙酸酯，薄荷醇及其任何混合物。

4. 发明专利

IL238036A A solid oral pharmaceutical formulation containing ticagrelor 未知
公开(公告)号：IL238036A
公开(公告)日：2019-05-30
申请号：IL23803615
申请日：2015-03-30
申请人： ZENTIVA KS , SEDMAK GREGOR
发明人： SEDMAK GREGOR
IPC分类号： A61K9/00
摘要： The present solution provides a solid oral pharmaceutical formulation containing ticagrelor, in the chemical name (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]- 5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2- cyclopentanediol, comprising at least one non-hygroscopic filler and/or at least one non- hygroscopic binder, wherein neither the filler, nor the binder have any disintegration effect. Preparation of the formulation is possible by wet granulation or dry granulation or direct

5. 发明申请

WO2011161223A2 PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING LERCANIDIPINE AND ENALAPRIL AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS 审中-公开
标题翻译：包含LERCANIDIPINE和ENALAPRIL及其药物接受口服的药物口服剂型
公开(公告)号：WO2011161223A2
公开(公告)日：2011-12-29
申请号：PCT/EP2011/060584
申请日：2011-06-23
申请人： KRKA, tovarna zdravil, d.d., Novo mesto , SEDMAK, Gregor , TURK, Urska , BUKOVEC, Polona
发明人： SEDMAK, Gregor , TURK, Urska , BUKOVEC, Polona
IPC分类号： A61K9/20 , A61K31/4422
CPC分类号： A61K9/2077 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/209 , A61K9/5084 , A61K31/401 , A61K31/4422 , A61K2300/00
摘要： The invention relates to unitary pharmaceutical oral dosage forms of the active substances lercanidipine and enalapril, as well the pharmacologically acceptable salts thereof, characterized in that the pharmaceutical oral dosage form comprise separate entities of lercanidipine or its pharmaceutically acceptable salts and enalapril or its pharmaceutically acceptable salts.
摘要翻译：本发明涉及活性物质lercanidipine和依那普利的单一药物口服剂型，以及其药理学上可接受的盐，其特征在于药物口服剂型包括氯卡地平或其药学上可接受的盐和依那普利或其药学上可接受的盐。

6. 发明申请

WO2010146187A2 PROCESS FOR THE PREPARATION OF TELMISARTAN 审中-公开
标题翻译：制备泰米斯坦的方法
公开(公告)号：WO2010146187A2
公开(公告)日：2010-12-23
申请号：PCT/EP2010/058754
申请日：2010-06-21
申请人： KRKA, tovarna zdravil, d.d., Novo mesto , ZUPANCIC, Silvo , SEDMAK, Gregor
发明人： ZUPANCIC, Silvo , SEDMAK, Gregor
IPC分类号： C07D235/20 , A61K31/4184 , A61P9/12
CPC分类号： C07D235/20
摘要： The invention relates to processes for preparing telmisartan or a pharmaceutically acceptable salt thereof as well as to a process for preparing a telmisartan cyano intermediate. Moreover, the invention relates to a multilayer pharmaceutical tablet comprising (a) at least one first tablet layer comprising 1 to 50 wt. -% telmisartan or a pharmaceutically acceptable salt thereof by weight of the first tablet layer and (b) at least one second tablet layer comprising 1 to 50 wt.-% of a diuretic and 50 to 99 wt.-% of at least one filler by weight of the second tablet layer, wherein the combined weight of the diuretic and the at least one filler is at least 87 wt.-% by weight of the second tablet layer. The invention also relates to a process for the preparation of a multilayer pharmaceutical tablet.
摘要翻译：本发明涉及制备替米沙坦或其药学上可接受的盐以及制备替米沙坦氰基中间体的方法。此外，本发明涉及一种多层药物片剂，其包含（a）至少一种第一片剂层，其包含1至50重量％ - 替米沙坦或其药学上可接受的盐，和（b）至少一个第二片剂层，其包含1至50重量％的利尿剂和50至99重量％的至少一种填料的第二片剂层，其中利尿剂和至少一种填料的组合重量为第二片剂层的至少87重量％。本发明还涉及制备多层药物片剂的方法。

7. 发明申请

WO2010136193A1 PHARMACEUTICAL COMPOSITION COMPRISING TAMSULOSIN 审中-公开
标题翻译：包含TAMSULOSIN的药物组合物
公开(公告)号：WO2010136193A1
公开(公告)日：2010-12-02
申请号：PCT/EP2010/003202
申请日：2010-05-26
申请人： KRKA, tovarna zdravil, d.d., Novo mesto , SEDMAK, Gregor , STEFANIC, Marko
发明人： SEDMAK, Gregor , STEFANIC, Marko
IPC分类号： A61K9/20 , A61K9/16
CPC分类号： A61K47/10 , A61K9/1641 , A61K9/2031 , A61K9/2866
摘要： The present invention relates to a pharmaceutical composition comprising tamsulosin or a pharmaceutically acceptable salt or solvate thereof in a solid dosage form and to a process for preparing such a composition.
摘要翻译：本发明涉及包含固体剂型的坦索罗辛或其药学上可接受的盐或溶剂合物的药物组合物以及制备这种组合物的方法。

8. 发明申请

WO2009004064A1 PROCESS FOR PREPARING TELMISARTAN 审中-公开
标题翻译：制备TELMISARTAN的方法
公开(公告)号：WO2009004064A1
公开(公告)日：2009-01-08
申请号：PCT/EP2008/058616
申请日：2008-07-03
申请人： KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO , ZUPET, Rok , JIANG, Xiangrui , OU, Yang , LIU, Yongjian , CHEN, Weiming , WU, Mingjun , SHEN, Jingshan , ZUPANCIC, Silvo , SEDMAK, Gregor
发明人： ZUPET, Rok , JIANG, Xiangrui , OU, Yang , LIU, Yongjian , CHEN, Weiming , WU, Mingjun , SHEN, Jingshan , ZUPANCIC, Silvo , SEDMAK, Gregor
IPC分类号： C07D235/08 , C07D235/18 , C07D235/20 , A61K31/4184 , A61P9/12
CPC分类号： C07D235/20 , C07D235/08 , C07D235/18
摘要： Novel processes for preparing a telmisaitan nitrile intermediate (4'-[{2-n-propyl-4- methyI-6-f l-methyJbenzimidazol-2-yl)-benzimidazol- l -yl)-methyl]-biphenyl-2-nitrile) and further converting it to telmisaitan and/or salts thereof are disclosed.
摘要翻译：制备替米沙坦腈中间体（4' - [{2-正丙基-4-甲基-6- [1-甲基-1H-咪唑-2-基] - 苯并咪唑-1-基） - 甲基]联苯-2-基的新方法腈）并进一步转化为替米沙坦和/或其盐。

9. 发明申请

WO2010146179A3 SOLID PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN 审中-公开
公开(公告)号：WO2010146179A3
公开(公告)日：2010-12-23
申请号：PCT/EP2010/058680
申请日：2010-06-18
申请人： KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO , SEDMAK, Gregor , VRECER, Franc , MEZNAR, Klavdija , TROST, Sabina , BUKOVEC, Polona , HVALEC, Miran
发明人： SEDMAK, Gregor , VRECER, Franc , MEZNAR, Klavdija , TROST, Sabina , BUKOVEC, Polona , HVALEC, Miran
IPC分类号： A61K9/20 , A61K31/5377
摘要： The invention relates to a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. The invention also relates to a process for the preparation of a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, the process comprising (a) providing a mixture comprising rivaroxaban and at least one pharmaceutically acceptable excipient and (b) converting said mixture to a solid pharmaceutical composition.

10. 发明申请

WO2009013237A2 STABLE SOLID PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN OR PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF 审中-公开
标题翻译：稳定的固体药物组合物，包括糖蜜或药物接受形式
公开(公告)号：WO2009013237A2
公开(公告)日：2009-01-29
申请号：PCT/EP2008/059451
申请日：2008-07-18
申请人： KRKA, D.D. NOVO MESTO , SEDMAK, Gregor , TURK, Urska , SMRKOLJ, Matej , ZUPANCIC, Silvo
发明人： SEDMAK, Gregor , TURK, Urska , SMRKOLJ, Matej , ZUPANCIC, Silvo
IPC分类号： A61K9/20 , A61K9/48 , A61K31/4184
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/205 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K31/4184
摘要： The invention relates to a stable solid pharmaceutical composition comprising candesartan or its pharmaceutically acceptable forms and at least one plasticizer selected from the group consisting of phthalate esters, sebacates, alginates, citrate esters, polyacrylate and polymethacrylate polymers, polymers and copolymers of ethylene, vinyl and/or acetate, various sugar alcohols, triacetin, menthol and any mixture thereof.
摘要翻译：本发明涉及包含坎地沙坦或其药学上可接受的形式的稳定的固体药物组合物和至少一种选自邻苯二甲酸酯，癸二酸酯，藻酸盐，柠檬酸酯，聚丙烯酸酯和聚甲基丙烯酸酯聚合物的增塑剂，乙烯，乙烯基和 /或乙酸盐，各种糖醇，三醋精，薄荷醇及其任何混合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式